Cellular Immunotherapy: CAR-T

A new wave of experimental cancer drugs that directly recruit the immune system’s powerful T cells could begin reaching patients next year, according to companies presenting new data at the annual meeting of the American Society of Clinical Oncology. In interviews with Reuters, Kite Pharma Inc

Chimeric Antigen Receptor T-cell therapy: targeted, specific, individualised. The pinnacle of immunotherapy for cancer, infection and autoimmunity.

Novartis says 82 percent of leukemia patients in remission after CAR-T

Image result for chimeric antigen receptor t cells

An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated…

Novartis beats Juno Therapeutics to report encouraging proof-of-concept results of Chimeric Antigen Receptor in T-cells (CAR-T) immunotherapy in cancer.

Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells

Figure thumbnail fx1

Modified CAR-T cells can be used as in vivo…

Controlling immune cells with light during the cancer-immunity cycle

“Controlling immune cells with light during the #cancer – immunity cycle: Zhou&co @TAMU discuss emerging tools in @TrendsinBiotech”
twitter.com|By Trends in Immunology